

OPINION

Nasal therapy—The missing link in optimising strategies to improve prevention and treatment of COVID-19

Norman A. Ratcliffe^{1,2*}, Helena C. Castro¹, Izabel C. Paixão^{1,3}, Victor G. O. Evangelho¹, Patricia Azambuja^{1,4}, Cicero B. Mello^{1,4}

1 Programa de Pós-Graduação em Ciências e Biotecnologia, IB, Universidade Federal Fluminense, Niterói, Brazil, **2** Department of Biosciences, Swansea University, Swansea, United Kingdom, **3** Laboratório de Virologia Molecular e Biotecnologia Marinha, IB, Universidade Federal Fluminense, Niterói, Brazil, **4** Laboratório de Bioquímica e Biotecnologia, IB, Universidade Federal Fluminense, Niterói, Brazil

* n.a.ratcliffe@swansea.ac.uk

The bottom line

Recent reports of the transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by fully vaccinated people [1] do not undermine the value of injected vaccines that continue to protect against serious illness and hospitalisation. They are, however, an early warning for immediate action to develop new drugs and approaches against Coronavirus Disease 2019 (COVID-19). The logical answer is to target the initial nasal portal of COVID-19 entry into the body with prophylactic drugs, which, together with injected vaccines, could potentially completely prevent infection and subsequent transmission of a range of variants. This paper outlines published work in this vital area in the hope that it becomes an urgent priority for development.



OPEN ACCESS

Citation: Ratcliffe NA, Castro HC, Paixão IC, Evangelho VGO, Azambuja P, Mello CB (2021) Nasal therapy—The missing link in optimising strategies to improve prevention and treatment of COVID-19. PLoS Pathog 17(11): e1010079. <https://doi.org/10.1371/journal.ppat.1010079>

Editor: Jeffrey D. Dvorin, Boston Children's Hospital, UNITED STATES

Published: November 24, 2021

Copyright: © 2021 Ratcliffe et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The authors received no specific funding for this work.

Competing interests: "The authors have declared that no competing interests exist."

COVID-19 variants

Over 12,000 mutations have been catalogued in SARS-CoV-2 genomes [2] and have resulted in new SARS-CoV-2 variants, including those identified in South Africa (B.1.351), United Kingdom (B.1.1.7), California (B.1.427 and B.1.429), Brazil (P.1 and P.2), India (B.1.617.2 = Delta), Peru (C.37 = Lambda), and Colombia (Mu). Such variants may have increased transmissibility and pathogenicity, higher viral loads, and vaccine resistance [3–5].

A missed opportunity

Vaccines provide short-term relief from COVID-19, but rapid evolution of resistant viral variants necessitates additional supportive strategies, including broad-spectrum antiviral agents coupled with innovative prophylactic and therapeutic processes. Antiviral agents against SARS-CoV-2 should have been repurposed drugs, but of all the drugs tested, those effective in the later stages of infection, such as dexamethasone, are the main ones granted approval for emergency use [6]. One exception has been monoclonal antibody therapy [7]. An important missing link has been the lack of innovative drug development for treating the early stages of COVID-19 infection. Disease pathology extols studying the initial interactions of invading pathogens with the body, involving adsorption, colonisation, penetration, multiplication, and host innate immunity [8].

COVID-19 entry portal

The main entry of SARS-CoV-2 occurs in the ciliated epithelium lining the nose [9–11]. The importance of the nasal epithelium in host invasion, involving the specific attachment of influenza and other viruses to the ciliated cells, was reported over 50 years ago [12]. These ciliated cells have the highest expression levels, in the airways of the body, of the SARS-CoV-2 entry receptors, angiotensin converting enzyme 2 (ACE2), and the viral entry-associated protease, transmembrane serine protease 2 (TMPRSS2) [9–11]. SARS-CoV-2 binds to these using the receptor-binding domain (RBD) of the virus spike protein [13]. Following attachment and entry into the nasal epithelium, the virus multiplies, spreading around the body [11]. To emphasise, the ciliated cells of the nasal mucosa are the main host entry targets for the virus, so that denying access of SARS-CoV-2 to the entry receptors by intranasal drug prophylaxis needs prioritising.

New opportunities—Nasal therapy

Most SARS-CoV-2 vaccines are injected and mainly induce serum immunoglobulin G1 (IgG1), which enters and protects the lungs, leaving the nasal epithelia and upper respiratory tract largely unprotected. Any serum immunoglobulin A1 (IgA1) produced by vaccination is not effectively transported to the secretions of the upper respiratory tract including those of the nasal mucosa [14]. The dynamics of the mucosal immune response to COVID-19 is largely neglected, although the IgA secreted is 7 times more potent than IgG at neutralising SARS-CoV-2 [13–15]. Only natural infections induce both IgG1 to protect the lungs as well as IgA1 to protect the upper respiratory tract, including the nasal passages [16]. Thus, injected vaccines fail to fully address the main portal of virus entry into the body through the nose, and, yet, few, if any, drugs have been developed to kill the virus in this early stage.

The nose is therefore likely to remain a source of infective virus transmission even after parenteral vaccination, which fails to completely eliminate the virus in the nose [1,17]. A single intranasal vaccination in rhesus macaques prevented SARS-CoV-2 infection in both the upper and lower respiratory tracts [18]. Parenteral vaccination and nasal therapy combined could realise the ultimate goal of completely eliminating these viral pathogens and sterilising the nose.

Intranasal drug candidates

Drugs for nasal pharmacological prophylaxis against COVID-19 are under development and include (1) those blocking virus attachment to the host entry receptors without involving host immunity; and (2) intranasal vaccines or immune stimulants eliciting antiviral antibodies and memory cells at the mucosal surface.

- **Category 1:** Include povidone-iodine [19], nitric oxide [20], ethyl lauroyl arginate hydrochloride [21], astodrimer sodium (SPL7013) [22,23], iota-carrageenan [24–26], and many others. These utilise nasal sprays and are at different stages of development globally. One very significant study for prevention of the early phase of SARS-CoV-2 entry into the body utilises poly(lactic-co-glycolic acid) nanoparticles to deliver and confine drugs specifically to treat the nasal sinuses with slow release over one week [27]. Stringent published clinical trials of these drugs are needed to satisfy the regulatory bodies as these may become available for sale to the public. Once approved, however, they could have enormous impacts on COVID-19 prophylaxis and therapy, particularly in deprived countries, as they are cheap and convenient and could also deal with breakthrough virus to sterilise the nose. They might be more acceptable too to those refusing injected vaccines.

- **Category 2:** Intranasal vaccines are also being developed, inducing IgA since dimeric forms of these antibodies are particularly potent and found at the mucosal surfaces where SARS-CoV-2 targets the cells [14].

Previous studies to develop nasal therapy for respiratory viruses have met with variable success. For example, a live attenuated flu nasal spray vaccine, called Flu Mist, has been approved by the US Food and Drug Administration (FDA), although the results of clinical trials have been discordant [28]. Developing nasal sprays with some respiratory viruses can be problematic, epitomised by the common cold and the work of David Tyrell [29] who showed that more than 100 different viruses may be involved. SARS-CoV-2, however, is more promising since few variants dominate the pandemic and parenteral vaccines have already been produced. Pre-clinical and clinical trials with a variety of drugs for nasal therapy against COVID-19 are also underway. For example, the nasal delivery of IgG monoclonal antibodies against SARS-CoV-2 engineered into immunoglobulin M (IgM) antibodies protect against virus variants in rats [30], while intranasal vaccination with the AstraZeneca vaccine, AZD1222, reduces virus concentrations in nasal swabs in 2 different SARS-CoV-2 animal models [31]. Furthermore, transgenic mice receiving one intranasal dose of an adenovirus-vectored vaccine, ChAd-SARS-CoV-2-S, also conferred superior immunity to SARS-CoV-2 than 2 intramuscular injections and evidenced sterilisation immunity in the upper respiratory tract [32]. Additional progress has been made in India with the approval of a human Phase II clinical trial of a COVID-19 nasal vaccine [33]. There will inevitably be delays and setbacks due to our lack of understanding of the dynamics of intranasal vaccination for COVID-19 so that additional research is urgently required [14,34,35]. Meanwhile, some Category 1 drugs may be approved more rapidly and available to prevent viral shedding following full vaccination against Delta and other variants [23–25].

In conclusion, nasal therapy has great potential to prevent and treat a variety of respiratory viruses. As patients present at different stages of COVID-19 or with other viral infections, we will need a selection of therapeutic strategies from vaccines to broad-spectrum antiviral drugs, delivered in different ways from injection, sprays/inhalations, and tablets alone or in combinations, to counter these threats.

Acknowledgments

The authors would like to thank the Universidade Federal Fluminense, Niteroi, Rio de Janeiro, Brazil for support and the facilities provided for the development of this article.

References

1. CDC (Centers for Disease Control and Prevention). Interim Public Health Recommendation for Fully Vaccinated People. Updated 2021 Jul 28.
2. Callaway E. The corona virus is mutating—does it matter? *Nature*. Sep 2020; 585(7824):174–7. <https://doi.org/10.1038/d41586-020-02544-6> PMID: 32901123.
3. WHO (World Health Organisation). COVID-19 Weekly Epidemiological Update—ReliefWeb. 2021 Jul 27.
4. Gomez CE, Perdigero B, Esteban M. Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19. *Vaccine*. 2021; 9(3):243. <https://doi.org/10.3390/vaccines9030243> PMID: 33799505; PubMed Central PMCID: PMC7999234.
5. Toledo K. Study suggests the Brazilian variant emerged in November, is more transmissible and can cause reinfection. The State of São Paulo Research Foundation (FAPESP) News. 2021 Mar 17. Available from: <https://fapesp.br/6028/fapesp>
6. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in Hospitalized Patients with Covid-19. *N Engl J Med*. 2021; 384:693–704. <https://doi.org/10.1056/NEJMoa2021436> PMID: 32678530; PubMed Central PMCID: PMC7383595.

7. FDA (USA Food and Drug Administration). Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibodies for Treatment of COVID-19. 2021 Feb 9. Available from: <https://www.fda.gov/media/145801/download>
8. Janeway CA Jr, Travers P, Walport M, Shlomchik MJ. Immunobiology: The Immune System in Health and Disease. 5th ed. New York: Garland Science; 2001. Infectious agents and how they cause disease. ISBN-10: 0-8153-3642-X.
9. Hou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH 3rd, et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. *Cell*. 2020 Jul 23; 182(2):429–446. e14. Epub 2020 May 27. <https://doi.org/10.1016/j.cell.2020.05.042> PMID: 32526206; PubMed PMCID: PMC7250779.
10. Sungnak W, Huang N, Bécavin C, Berg M, Queen R, Litvinukova M, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. *Nat Med*. 2020; 26:681–7. <https://doi.org/10.1038/s41591-020-0868-6> PMID: 32327758.
11. Gallo O, Locatello LG, Mazzoni A, Novelli L, Annunziato F. The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection. *Mucosal Immunol*. 2021; 14:305–16. <https://doi.org/10.1038/s41385-020-00359-2> PMID: 33244161; PubMed Central PMCID: PMC7690066.
12. Gould EA, Ratcliffe NA, Basarab O, Smith H. Studies of the basis of localization of influenza virus in ferret organ cultures. *Br J Exp Pathol*. 1972 Feb; 53 (1):31–6. PMID: 5014240; PubMed Central PMCID: PMC2072377.
13. Matuchansky C. Mucosal immunity to SARS-CoV-2: a clinically relevant key to deciphering natural and vaccine-induced defences [published online ahead of print, 2021 Aug 12]. *Clin Microbiol Infect*. 2021; S1198-743X(21)00465-1. <https://doi.org/10.1016/j.cmi.2021.08.008> PMID: 34391929. PubMed PMCID: PMC8358136.
14. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. Mucosal immunity in COVID-19: A neglected but critical aspect of SARS-CoV-2 infection. *Front Immunol*. 2020; 11:611337. <https://doi.org/10.3389/fimmu.2020.611337> PMID: 33329607; PubMed Central PMCID: PMC7733922.
15. Wisnewski AV, Campillo Luna J, Redlich CA. Human IgG and IgA responses to COVID-19 mRNA vaccines. *PLoS ONE*. 2021; 16(6):e0249499. PubMed Central PMCID: PMC8208542. <https://doi.org/10.1371/journal.pone.0249499> PMID: 34133415
16. Krammer F. SARS-CoV-2 vaccines in development. *Nature*. 2020 Oct; 586(7830):516–527. Epub 2020 Sep 23. <https://doi.org/10.1038/s41586-020-2798-3> PMID: 32967006.
17. Subbaraman N. How do vaccinated people spread Delta? What the science says. *Nature*. 2021 Aug; 596(7872):327–8. <https://doi.org/10.1038/d41586-021-02187-1> PMID: 34385613.
18. Hassan AO, Feldmann F, Zhao H, Curiel DT, Okumura A, Tang-Huai T-L. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques. *Cell Rep Med*. 2021; 2:100230. <https://doi.org/10.1016/j.xcrm.2021.100230> PMID: 33754147; PubMed Central PMCID: PMC7969912.
19. de Toledo Telles-Araujo G, Caminha RDG, Kallás MS, Sipahi AM, da Silva Santos PS. Potential mouth rinses and nasal sprays that reduce SARS-CoV-2 viral load: What we know so far? *Clinics (Sao Paulo)*. 2020; 75:e2328. Published 2020 Nov 27. <https://doi.org/10.6061/clinics/2020/e2328> PMID: 33263622
20. Winchester S, John S, Jabbar K, John I. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection. *J Infect*. 2021 Aug; 83(2):237–279. Epub 2021 May 13. <https://doi.org/10.1016/j.jinf.2021.05.009> PMID: 33992687; PMCID: PMC8117664.
21. Jimenez D. Nothing to sneeze at: nasal sprays to tackle Covid-19. 2021 Pharmaceutical Technology Newsletter. 2021 Jul 27.
22. McCarthy TD, Karella P, Henderson SA, Giannis M, O'Keefe DF, Heery G, et al. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. *Mol Pharm*. 2005; 2(4):312–8. <https://doi.org/10.1021/mp050023q> PMID: 16053334.
23. Paull JRA, Castellarnau A, Luscombe CA, Fairley JK, Heery GP. Astodrimer sodium, dendrimer antiviral, inhibits replication of SARS-CoV-2 *in vitro*. *Antiviral Res*. 16 May 2021; 191:105089. <https://doi.org/10.1016/j.antiviral.2021.105089> PMID: 34010661; PubMed Central PMCID: PMC8126375.
24. Morokutti-Kurz M, Fröba M, Graf P, Große M, Grassauer A, Auth J, et al. Iota-Carrageenan neutralizes SARS-CoV-2 and inhibits viral replication *in vitro*. *PLoS ONE*. 2021; 16(2):e0237480. <https://doi.org/10.1371/journal.pone.0237480> PMID: 33596218; PubMed Central PMCID: PMC7888609.
25. Figueroa JM, Lombardo M, Dogliotti A, Flynn LP, Giugliano RP, Simonelli G, et al. Efficacy of a nasal spray containing Iota-Carrageenan in the prophylaxis of COVID-19 in hospital personnel dedicated to patients care with COVID-19 disease A pragmatic multicenter, randomized, double-blind, placebo-controlled trial (CARR-COV-02). *medRxiv*. <https://doi.org/10.1371/journal.pone.0237480> PMID: 33596218.

26. Eccles R. Iota-Carrageenan as an antiviral treatment for the common cold. *Open Virol J.* 2020; 14:9–15. <https://doi.org/10.2174/1874357902014010009>
27. Far J, Abdel-Haq M, Gruber M, Abu AA. Developing biodegradable nanoparticles loaded with mometasone furoate for potential nasal drug delivery. *ACS Omega.* 2020 Mar 25; 5(13):7432–9. <https://doi.org/10.1021/acsomega.0c00111> PMID: 32280885; PubMed Central PMCID: PMC7144157.
28. FDA (US Food and Drug Administration). FDA Information Regarding FluMist Quadrivalent Vaccine. 2018 Jan 28.
29. Tyrrell D, Fielder M. Cold Wars: The Fight Against the Common Cold. 1st ed. Oxford University Press. p. 253. ISBN.
30. Ku Z, Xie X, Hinton PR, Liu X, Ye X, Muruato AE, et al. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. *Nature.* 2021; 595:718–723. <https://doi.org/10.1038/s41586-021-03673-2> PMID: 34082438.
31. van Doremalen N, Purushotham JN, Schulz JE, Holbrook MG, Bushmaker T, Carmody A, et al. Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. *Sci Transl Med.* 2021 Jul 27:eabhb0755. <https://doi.org/10.1126/scitranslmed.abh0755> Online ahead of print. PMID: 34315826.
32. Hassan AO, Kafai NM, Dmitriev IP, Fox JM, Smith BK, Harvey IB, et al. A single-dose intranasal ChAd Vaccine protects upper and lower respiratory tracts against SARS-CoV-2. *Cell.* 2020 Oct 1; 183(1):169, e13–84. <https://doi.org/10.1016/j.cell.2020.08.026> PMID: 32931734; PubMed Central PMCID: PMC7437481.
33. Clinical Trials Arena News. Bharat Biotech obtains approval for Phase II COVID-19 nasal vaccine trial. 2021 Aug 16.
34. Lavelle EC, Ward RW. Mucosal vaccines—fortifying the frontiers. Epub ahead of print. *Nat Rev Immunol.* Erratum in: *Nat Rev Immunol.* 2021 Jul 26, 2021 Aug 3:1–15. <https://doi.org/10.1038/s41577-020-00486-8> PMID: 33303954; PubMed Central PMCID: PMC8312369.
35. Park JH, Lee HK. Delivery routes for COVID-19 vaccines. *Vaccines (Basel).* 2021 May 19; 9(5):524. <https://doi.org/10.3390/vaccines9050524> PMID: 34069359; PubMed Central PMCID: PMC8158705.